Xponance’s CG Oncology CGON Stock Holding History

Xponance’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$515K	Buy	7,246 +1,777	+32%	+$116K	﹤0.01%	1090
2026 Q1	$370K	Buy	+5,469	New	+$310K	﹤0.01%	1160

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Xponance's CGON Position: Q2 2026 in Review

Xponance increased its CG Oncology (CGON) stake by 32% in Q2 2026, buying an estimated $116K and bringing the position to 7,246 shares worth $515K. The position accounts for ﹤0.01% of the portfolio, ranked #1090.

Xponance first reported a position in CGON in Q1 2026 and has held it in 2 quarters since. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

Xponance held 7,246 shares of CG Oncology worth $515K as of Q2 2026.
Xponance bought 1,777 CG Oncology shares in Q2 2026, an estimated $116K.
CG Oncology made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1090 holding.
Xponance first reported a position in CG Oncology in Q1 2026 and has held it in 2 quarters since.
228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.